Familial amyloid polyneuropathy.
Planté-Bordeneuve V, Said G.
Lancet Neurol. 2011 Dec;10(12):1086-97. doi: 10.1016/S1474-4422(11)70246-0.
Familial amyloid polyneuropathy.
Adams D, Cauquil C, Labeyrie C.
Curr Opin Neurol. 2017 Oct;30(5):481-489. doi: 10.1097/WCO.0000000000000476.
Estimating the global prevalence of transthyretin familial amyloid polyneuropathy.
Schmidt HH, Waddington-Cruz M, Botteman MF, Carter JA, Chopra AS, Hopps M, Stewart M, Fallet S, Amass L.
Muscle Nerve. 2018 May;57(5):829-837. doi: 10.1002/mus.26034. Epub 2018 Feb 1.
Familial amyloid polyneuropathy.
Barreiros AP, Galle PR, Otto G.
Dig Dis. 2013;31(1):170-4. doi: 10.1159/000347214. Epub 2013 Jun 17.
Familial amyloid polyneuropathy.
Reilly MM, King RH.
Brain Pathol. 1993 Apr;3(2):165-76. doi: 10.1111/j.1750-3639.1993.tb00741.x.
Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment?
Adams D, Beaudonnet G, Adam C, Lacroix C, Théaudin M, Cauquil C, Labeyrie C.
Rev Neurol (Paris). 2016 Oct;172(10):645-652. doi: 10.1016/j.neurol.2016.08.007. Epub 2016 Sep 21.
Transthyretin familial amyloid polyneuropathy: an update.
Plante-Bordeneuve V.
J Neurol. 2018 Apr;265(4):976-983. doi: 10.1007/s00415-017-8708-4. Epub 2017 Dec 16.
Transthyretin familial amyloid polyneuropathy.
Planté-Bordeneuve V, Kerschen P.
Handb Clin Neurol. 2013;115:643-58. doi: 10.1016/B978-0-444-52902-2.00038-2.
Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment.
Adams D, Sekijima Y, Conceição I, Waddington-Cruz M, Polydefkis M, Echaniz-Laguna A, Reilly MM.
Lancet Neurol. 2023 Nov;22(11):1061-1074. doi: 10.1016/S1474-4422(23)00334-4.
Neuropathy Associated with Systemic Amyloidosis.
Kaku M, Berk JL.
Semin Neurol. 2019 Oct;39(5):578-588. doi: 10.1055/s-0039-1688994. Epub 2019 Oct 22.
